**Pharmaceutical sales:** 80%
**Research and development:** 10%
**Medical devices:** 10%

**TOP 3 markets:**
**China:** 60%
**USA:** 20%
**Europe:** 10%

Jiangsu Hengrui Pharmaceuticals Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, particularly through the sale of drugs and pharmaceutical products. A smaller portion of revenue comes from research and development as well as the sale of medical devices.

The company's largest market is China, where it generates 60% of its revenue. This is due to its strong local presence and high demand for pharmaceutical products. The USA and Europe follow as important markets, accounting for 30% of revenues together. The expansion into these international markets is supported by the introduction of new products and adaptation to local regulations.

**Production sites of Jiangsu Hengrui Pharmaceuticals:**

- **Headquarters and main production site:** Lianyungang, Jiangsu, China
- **Other production sites:** Several locations within China, including in the provinces of Jiangsu and Sichuan.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. is one of the leading pharmaceutical companies in China and has mainly established its production capacities within the country. The headquarters in Lianyungang serves as a central hub for research, development, and production. In addition to the headquarters, the company has expanded its production capacities in various regions of China to meet the increasing demand both in the domestic and international markets.

**Focus on Research and Development:** 15% of revenue (2024)

**International Expansion:** Increasing presence in the USA and Europe

**Diversification of the Product Portfolio:** Introduction of new oncology and biopharmaceuticals

Jiangsu Hengrui Pharmaceuticals Co., Ltd pursues a strategy that strongly focuses on research and development. In 2024, the company invested about 15% of its revenue in this area to develop innovative drugs and strengthen its competitiveness.

Another focus is on international expansion, especially in the USA and Europe. Hengrui plans to increase its market presence in these regions through strategic partnerships and the establishment of local production facilities.

Additionally, the company is diversifying its product portfolio by introducing new oncology and biopharmaceuticals. These measures are intended to drive growth and position the company as a leading player in the global pharmaceutical market.

**Main raw materials:** Active ingredients (APIs), chemicals, packaging materials
**Countries of origin:** USA, Germany, India, China

Jiangsu Hengrui Pharmaceuticals Co., Ltd imports a variety of raw materials necessary for the production of pharmaceutical products. These include in particular active ingredients (APIs), special chemicals, and packaging materials.

The USA and Germany are important suppliers of high-quality APIs and specialty chemicals needed in pharmaceutical production. India is also a significant partner, especially for generic APIs that can be produced cost-effectively. China itself also supplies raw materials, with a focus on availability and cost.

This international procurement enables Jiangsu Hengrui to produce high-quality products while remaining competitive.

**Market share in China:** approx. 10% (2024)
**R&D expenses:** 15% of revenue (2024)
**Patent portfolio:** Over 300 patents (2024)

Jiangsu Hengrui Pharmaceuticals Co., Ltd. has a significant competitive advantage in the Chinese pharmaceutical industry, especially due to its strong market presence and extensive investments in research and development. With a market share of around 10% in China, the company positions itself as one of the leading players in the pharmaceutical sector.

Another crucial advantage is the extensive patent portfolio with over 300 patents, providing Hengrui Pharmaceuticals with a solid foundation for innovation and protecting its products. The continuous investments in research and development, accounting for about 15% of revenue, highlight the company's commitment to expanding its product pipeline and developing new drugs.

Additionally, the company benefits from strong brand awareness and a broad distribution network, enabling it to effectively market and distribute its products. Together, these factors give Jiangsu Hengrui Pharmaceuticals a sustainable competitive advantage in a fiercely competitive market.

**Institutional investor share:** approx. 30% (2025, estimated)
**Insider purchases/sales:** No significant transactions in the last year (2025, estimated)

The institutional investor share in Jiangsu Hengrui Pharmaceuticals is around 30%. This indicates a moderate interest of institutional investors in the company, suggesting a certain stability and confidence in its long-term prospects.

In 2025, there were no significant insider transactions, indicating that the management and other insiders currently do not expect any major changes in the company's valuation. This can be seen as a sign of a stable internal assessment of the company's development.

**Market share of Jiangsu Hengrui Pharmaceuticals:** 8% (estimated for 2025)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd:** 12%
2. **Shanghai Pharmaceuticals Holding Co., Ltd:** 10%
3. **China Resources Pharmaceutical Group Limited:** 9%
4. **Jiangsu Hengrui Pharmaceuticals Co., Ltd:** 8%
5. **CSPC Pharmaceutical Group Limited:** 7%
6. **Huadong Medicine Co., Ltd:** 6%
7. **Shanghai Fosun Pharmaceutical (Group) Co., Ltd:** 5%
8. **Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd:** 4%
9. **Yunnan Baiyao Group Co., Ltd:** 3%
10. **Tonghua Dongbao Pharmaceutical Co., Ltd:** 2%

**Moat of Jiangsu Hengrui Pharmaceuticals:**

Jiangsu Hengrui Pharmaceuticals has a moderate moat, mainly characterized by its strong R&D investment and a broad product range in the oncology and anesthesia sectors. The company has invested significant resources in developing new drugs in recent years, giving it a technological advantage.

Compared to its competitors, Sinopharm has a stronger moat due to its extensive distribution networks and market leadership in the distribution of pharmaceutical products. Shanghai Pharmaceuticals and China Resources Pharmaceutical also benefit from extensive distribution networks and a diversified product range.

Jiangsu Hengrui's advantage lies in its innovation and specialization in specific therapy areas, giving it a strong position in niche markets. However, they must continue to invest in research and development to maintain and expand their competitiveness.

**Revenue growth:** 10.5% (2024)
**R&D expenses:** 18% of revenue (2024)
**Market share in China:** 7% (2024)

Jiangsu Hengrui Pharmaceuticals Co., Ltd recorded a revenue growth of 10.5% in 2024, attributed to a strong product pipeline and successful market launches. The company continues to heavily invest in research and development, at 18% of revenue, indicating a long-term strategy towards innovation and product diversification.

The 7% market share in China indicates that Hengrui holds a significant position in the domestic market. The ongoing investments in R&D and strong market position could support the potential for further growth and expansion into international markets.

Analysts may have a positive outlook on the company's long-term growth prospects due to these factors. The strong focus on R&D and the significant market share suggest that Hengrui is well positioned to benefit from future developments in the healthcare sector.

**Dividend payment:** No dividend (2025)

Jiangsu Hengrui Pharmaceuticals Co., Ltd has not paid any dividends in recent years. The company has traditionally focused on reinvesting profits in research and development as well as expansion to strengthen its market position and drive innovation.

The reliability of dividend payments is therefore not guaranteed, as the company does not make regular payouts. Investors aiming for dividend yields should take this into account in their investment strategy.